Actively Recruiting
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Led by Acerand Therapeutics (Shanghai) Limited · Updated on 2025-12-29
298
Participants Needed
14
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors.
CONDITIONS
Official Title
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provide written informed consent
- Have advanced solid tumors that are difficult to treat or intolerant to standard treatments
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy of at least 3 months
- Measurable disease per RECIST 1.1; castration-resistant prostate cancer assessed by PCWG3
- Adequate organ and bone marrow function
- Ability to provide tumor specimens and blood samples for gene testing related to Homologous Recombination Deficiency (HRD) or Repair (HRR)
You will not qualify if you...
- Receiving anti-cancer drugs, major surgery, or radiation therapy within protocol-defined washout periods
- Using medications or herbal supplements that strongly or moderately affect cytochrome P450 3A4 (CYP3A4)
- Receiving continuous corticosteroids with prednisone dose greater than 10 mg/day or equivalent
- Unresolved previous treatment-related toxicities greater than Grade 1, except alopecia and certain Grade 2 toxicities
- Spinal cord compression or brain metastases unless asymptomatic, treated, and stable
- Severe cardiovascular disorders
- Myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), or evidence suggesting these conditions
- Conditions preventing absorption of the investigational product
- Active infections including HIV, hepatitis B or C, or tuberculosis
- Other malignancies requiring treatment within 3 years prior to the first dose
- Conditions expected to rapidly deteriorate during screening
- Known allergy or hypersensitivity to the investigational product or its components
- Other medical conditions that may interfere with safety, treatment efficacy, or compliance as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 14 locations
1
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China
Actively Recruiting
2
Fujian Cancer Hospital
Fuzhou, Fujian, China
Actively Recruiting
3
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China
Actively Recruiting
4
Anyang Cancer Hospital
Anyang, Henan, China
Actively Recruiting
5
Henan Cancer Hospital
Zhengzhou, Henan, China
Actively Recruiting
6
Hubei Cancer Hospital
Wuhan, Hubei, China
Actively Recruiting
7
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Actively Recruiting
8
Hunan Cancer Hospital
Changsha, Hunan, China
Actively Recruiting
9
Jinan Central Hospital
Jinan, Shandong, China
Actively Recruiting
10
Qilu Hospital Shangdong University
Jinan, Shandong, China
Actively Recruiting
11
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Actively Recruiting
12
Second Hospital Affiliated to Shanxi Medical University
Taiyuan, Shanxi, China
Actively Recruiting
13
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Actively Recruiting
14
First Hospital Affiliated to Wenzhou Medical University
Wenzhou, Zhejiang, China
Actively Recruiting
Research Team
T
Teresa Shi
CONTACT
S
Sherwin Cai, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here